The European Union’s Artificial Intelligence Act represents the most comprehensive regulatory framework for AI systems globally. For US healthcare organizations, the implications extend far beyond European borders through the Act’s extraterritorial provisions.

Organizations serving European patients, utilizing EU-based AI systems, or deploying AI outputs that affect EU residents must understand their compliance obligations. The Act’s risk-based classification system places particular scrutiny on healthcare AI applications, categorizing many as ‘high-risk’ systems subject to stringent requirements.

High-risk AI systems in healthcare face mandatory requirements including risk management systems, data governance protocols, technical documentation, record-keeping, transparency provisions, human oversight mechanisms, and accuracy, robustness, and cybersecurity standards.

US healthcare organizations should begin by conducting an inventory of AI systems with potential EU touchpoints. This assessment should examine data flows, patient populations, and vendor relationships to identify systems potentially within scope.

Compliance pathways vary based on organizational role. AI system providers face the most extensive obligations, while deployers and distributors have proportionate but still significant requirements. Many US healthcare organizations will find themselves in deployer roles, requiring conformity assessments and ongoing monitoring.

Risk mitigation strategies should address both current deployments and future AI adoption. Organizations should establish governance frameworks that anticipate EU AI Act requirements, even for systems not currently in scope, as regulatory convergence is likely.

The timeline for compliance creates urgency. Prohibited AI practices take effect in early 2025, with high-risk system requirements following in 2026. Organizations should use this window to assess exposure, develop compliance roadmaps, and implement necessary governance structures.